-
公开(公告)号：US11773163B2
公开(公告)日：2023-10-03
申请号：US16462754
申请日：2017-11-21
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE STRASBOURG , ETABLISSEMENT FRANçAIS DU SANG (EFS)
发明人： Pierre Mangin , Christian Gachet
IPC分类号： A61K39/395 , C07K16/28 , A61P35/04 , C07K14/705 , C12N15/115 , A61K39/00
CPC分类号： C07K16/2803 , A61P35/04 , C07K14/70503 , C12N15/115 , A61K2039/505 , C07K2317/55 , C07K2317/565 , C07K2319/30 , C12N2310/16 , C12N2320/30
摘要： The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.
-
2.发明公开公开(公告)号：US20240319209A1
公开(公告)日：2024-09-26
申请号：US18578165
申请日：2022-07-15
申请人： INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) , ETABLISSEMENT FRANÇAIS DU SANG (EFS) , UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE
CPC分类号： G01N33/6893 , A61K31/17 , A61P7/06 , G01N2470/04 , G01N2800/22 , G01N2800/52
摘要： The Alpha haemoglobin-stabilising protein (AHSP) is a key chaperone molecule synthesised in red blood cell (RBC) precursors. In this study, the inventors have developed a sandwich ELISA method which allows the quantification of AHSP protein in RBCs of normal subjects and in sickle cell anaemia (SCA) patients treated or untreated by hydroxycarbamide. AHSP was significantly more abundant in untreated SCA patients than in controls (p
-
公开(公告)号：US11458118B2
公开(公告)日：2022-10-04
申请号：US16606236
申请日：2018-04-20
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE BRETAGNE OCCIDENTALE , ETABLISSEMENT FRANÇAIS DU SANG (EFS) , CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST
IPC分类号： A61K31/40 , A61P11/00 , A61K9/00 , C12N15/113
摘要： Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.
-
公开(公告)号：US20230324412A1
公开(公告)日：2023-10-12
申请号：US17995452
申请日：2021-04-08
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , ETABLISSEMENT FRANÇAIS DU SANG (EFS) , UNIVERSITÉ PARIS-EST CRÉTEIL VAL DE MARNE
CPC分类号： G01N33/721 , G01N33/6848
摘要： The present invention relates to a method for determining the quality of haemoglobin (Hb) during the storage period of red blood cell (RBC) units comprising a step of detecting soluble alpha-haemoglobin (α-Hb) pool in RBC lysates and concluding that the presence of α-Hb pool indicates a conservation of quality of Hb during the storage RBCs. Inventors have determined the impact of RBC units aging on the quality of Hb and on the soluble α-Hb pool level in RBCs. For this purpose, 21 RBC units were collected, stored at +4 to 6° C. and samples were taken at two different storage times (D3-D8 and D38-D42) to evaluate spectral characteristics of Hb and soluble α-Hb pool in RBCs. Two additional samples were collected from 16 RBC units, at intermediate time points during storage (D13-D17 and D24-D29; n=16). The α-Hb dosing assay uses the specific character of the interaction between the α-Hb and the AHSP, the α chaperone, to trap the α-Hb present in the RBC lysates of RBC units. They also investigated the effect of a short cryopreservation period at −80° C. for 15 days on the α-Hb pool for 4 different RBC units.
-
公开(公告)号：US11364271B2
公开(公告)日：2022-06-21
申请号：US17049221
申请日：2019-04-19
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Etablissement Français du Sang (EFS) , Université de Bretagne Occidentale , Centre Hospitalier Regional et Universitaire de Brest
发明人： Rozenn Le Berre , Marie-Sarah Fangous , Gwenaelle Le Blay , Geneviève Hery-Arnaud , Rosyne Lagrafeuille
IPC分类号： A01N63/00 , A61K35/747 , A61P31/04 , A61P11/00
摘要： Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectoration, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils. Thus the present relates to a method of treating a Pseudomonas aeruginosa respiratory tract infection in a patient in need thereof comprising administering to the patient's respiratory tract a therapeutically effective amount of at least one Lactobacillus strain.
-
公开(公告)号：US20210017584A1
公开(公告)日：2021-01-21
申请号：US17043100
申请日：2019-03-28
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST , UNIVERSITÉ DE BRETAGNE OCCIDENTALE , INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT , ETABLISSEMENT FRANÇAIS DU SANG (EFS)
发明人： Geneviève HERY-ARNAUD , Jérôme MOUNIER , Charles-Antoine GUILLOUX , Patricia LEPAGE , Stanislas MONDOT , Marlène KERAVEC
摘要： The present invention relates to methods for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa. The inventors analyzed the respiratory tract microbiota from 65 patients sputum samples and compared microbiota data. The inventors found that patients that will remain uninfected from P. aeruginosa exhibited 3-fold higher abundance of Porphyromonas catoniae compared to the other groups. In particular, the present invention relates to a method for predicting the risk of developing pulmonary colonization/infection by P. aeruginosa in a subject suffering from cystic fibrosis (CF) comprising measuring the abundance of Porphyromonas catoniae in a biological sample obtained from said subject.
-
公开(公告)号：US20190315862A1
公开(公告)日：2019-10-17
申请号：US16462754
申请日：2017-11-21
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE STRASBOURG , ETABLISSEMENT FRANÇAIS DU SANG (EFS)
发明人： Pierre MANGIN , Christian GACHET
IPC分类号： C07K16/28 , C12N15/115 , C07K14/705 , A61P35/04
摘要： The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.
-
公开(公告)号：US11903982B2
公开(公告)日：2024-02-20
申请号：US17740819
申请日：2022-05-10
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Etablissement Français du Sang (EFS) , Université de Bretagne Occidentale , Centre Hospitalier Regional et Universitaire de Brest
发明人： Rozenn Le Berre , Marie-Sarah Fangous , Gwenaelle Le Blay , Geneviève Hery-Arnaud , Rosyne Lagrafeuille
IPC分类号： A01N63/00 , A61K35/747 , A61P31/04 , A61P11/00
CPC分类号： A61K35/747 , A61P11/00 , A61P31/04
摘要： Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectorations, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils. Thus the present relates to a method of treating a Pseudomonas aeruginosa respiratory tract infection in a patient in need thereof comprising administering to the patient's respiratory tract a therapeutically effective amount of at least one Lactobacillus strain.
-
公开(公告)号：US20220331379A1
公开(公告)日：2022-10-20
申请号：US17740819
申请日：2022-05-10
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Etablissement Français du Sang (EFS) , Université de Bretagne Occidentale , Centre Hospitalier Regional et Universitaire de Brest
发明人： Rozenn LE BERRE , Marie-Sarah FANGOUS , Gwenaelle LE BLAY , Geneviève HERY-ARNAUD , Rosyne LAGRAFEUILLE
IPC分类号： A61K35/747 , A61P31/04 , A61P11/00
摘要： Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectorations, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils. Thus the present relates to a method of treating a Pseudomonas aeruginosa respiratory tract infection in a patient in need thereof comprising administering to the patient's respiratory tract a therapeutically effective amount of at least one Lactobacillus strain.
-
公开(公告)号：US20210236567A1
公开(公告)日：2021-08-05
申请号：US17049221
申请日：2019-04-19
申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Etablissement Français du Sang (EFS) , Université de Bretagne Occidentale , Gentre Hospitaller Regional et Universitaire de Brest
发明人： Rozenn LE BERRE , Marie-Sarah FANGOUS , Gwenaelle LE BLAY , Geneviève HERY-ARNAUD , Rosyne LAGRAFEUILLE
IPC分类号： A61K35/747 , A61P31/04 , A61P11/00
摘要： Pseudomonas aeruginosa (PA) leads to chronic respiratory infections especially in patients with cystic fibrosis patients and chronic obstructive pulmonary disease (COPD), characterized by a high morbidity. After screening Lactobacilli coming from CF expectoration, on their capacity to inhibit two Pseudomonas aeruginosa (PA) virulence factors (elastase, pyocyanin), the inventors evaluated the effect of intranasal administration of Lactobacilli on PA murine pneumonia. The primary outcome was the bacterial lung load 24 hours after PA induced pneumonia. To understand the role of Lactobacillus, the chemokines, the pro and anti-inflammatory BAL rates were also measured. The administration of Lactobacilli cocktail 18 h prior the PA lung infection decreases significantly the lung bacterial load at 24 h post-infection. Although the mechanisms need to be deeply explored, an immunomodulation effect may be involved, notably through the recruitment of neutrophils. Thus the present relates to a method of treating a Pseudomonas aeruginosa respiratory tract infection in a patient in need thereof comprising administering to the patient's respiratory tract a therapeutically effective amount of at least one Lactobacillus strain.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.015 秒)
